We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Finding Patterns In Clinical Study Experiences of Multiple Sclerosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05503524
Recruitment Status : Not yet recruiting
First Posted : August 16, 2022
Last Update Posted : August 16, 2022
Information provided by (Responsible Party):
Power Life Sciences Inc.

Brief Summary:

Participation in medical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This study will admit a wide range of data on the clinical trial experience of Multiple Sclerosis patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future Multiple Sclerosis patients.

Condition or disease
Multiple Sclerosis

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Extensive Clinical Trial Experiences of Multiple Sclerosis Patients To Determine Trial Attributes Affecting Completion Rates For Specific Demographic Groups
Estimated Study Start Date : September 10, 2022
Estimated Primary Completion Date : September 10, 2023
Estimated Study Completion Date : September 10, 2024

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Rate of patients who decide to enroll in a Multiple Sclerosis Clinical Trial [ Time Frame: 3 months ]
  2. Number of patients who remain in Multiple Sclerosis clinical trial until completion [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Multiple Sclerosis patients who are actively considering involvement in an interventional clinical trial, but have not yet completed enrollment and registration.

Inclusion Criteria:

  • Participant has a diagnosis of Multiple Sclerosis
  • Patient has self-identified as planning to enroll in an interventional clinical trial for Multiple Sclerosis
  • Patient is at least 18 years of age

Exclusion Criteria:

  • Inability to perform regular electronic reporting
  • Patient does not understand, sign, and return consent form
  • No diagnosis of Multiple Sclerosis confirmed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05503524

Layout table for location contacts
Contact: Michael B Gill 415-900-4227 bask@withpower.com

Sponsors and Collaborators
Power Life Sciences Inc.
Layout table for investigator information
Study Director: Michael B Gill Power Life Sciences Inc.
  Study Documents (Full-Text)

Documents provided by Power Life Sciences Inc.:
Informed Consent Form  [PDF] August 10, 2022

Layout table for additonal information
Responsible Party: Power Life Sciences Inc.
ClinicalTrials.gov Identifier: NCT05503524    
Other Study ID Numbers: 98852353
First Posted: August 16, 2022    Key Record Dates
Last Update Posted: August 16, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Power Life Sciences Inc.:
Multiple Sclerosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases